From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA approves first treatment for pediatric Lambert-Eaton myasthenic syndrome

from American Journal for Managed Care

The FDA has granted approval to the first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder. The drug, amifampridine (Ruzurgi), is approved for the treatment of patients aged six years to less than 17 years. LEMS affects the connection between nerves and muscles, causing weakness and other symptoms, and causing the immune system to attack the neuromuscular junction, which disrupts the ability of nerve cells to send signals to muscles. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063